Literature DB >> 17503128

Brain atrophy and cognitive impairment in multiple sclerosis: a review.

Michael Lanz1, Horst K Hahn, Helmut Hildebrandt.   

Abstract

Multiple sclerosis (MS) is a common neurological disease in the Western hemisphere that leads to neurological dysfunctions and frequently from its onset to cognitive impairment, which together predict quality of life. Recent pathological and imaging studies have focused on brain atrophy representing axonal injury and loss as being crucial for developing disability and neuropsychological impairment. Brain atrophy has therefore been proposed to be a tool for monitoring disease progress. Here, we review the possible origins of brain atrophy and its correlation with cognitive impairment in MS.

Entities:  

Mesh:

Year:  2007        PMID: 17503128     DOI: 10.1007/s00415-007-2011-8

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  24 in total

1.  Cognitive correlates of supratentorial atrophy on MRI in multiple sclerosis.

Authors:  S G Edwards; C Liu; L D Blumhardt
Journal:  Acta Neurol Scand       Date:  2001-10       Impact factor: 3.209

Review 2.  Inflammatory demyelination is not central to the pathogenesis of multiple sclerosis.

Authors:  Wolfgang Brück
Journal:  J Neurol       Date:  2005-11       Impact factor: 4.849

3.  Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosis.

Authors:  R H C Lazeron; J B Boringa; M Schouten; B M J Uitdehaag; E Bergers; J Lindeboom; M I Eikelenboom; P H Scheltens; F Barkhof; C H Polman
Journal:  Mult Scler       Date:  2005-10       Impact factor: 6.312

4.  Memory performance in multiple sclerosis patients correlates with central brain atrophy.

Authors:  H Hildebrandt; H K Hahn; J A Kraus; A Schulte-Herbrüggen; B Schwarze; G Schwendemann
Journal:  Mult Scler       Date:  2006-08       Impact factor: 6.312

5.  Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis.

Authors:  M J Hohol; C R Guttmann; J Orav; G A Mackin; R Kikinis; S J Khoury; F A Jolesz; H L Weiner
Journal:  Arch Neurol       Date:  1997-08

6.  Corpus callosum axonal injury in multiple sclerosis measured by proton magnetic resonance spectroscopic imaging.

Authors:  Joonmi Oh; Daniel Pelletier; Sarah J Nelson
Journal:  Arch Neurol       Date:  2004-07

Review 7.  Neuropsychological aspects of multiple sclerosis.

Authors:  J C Brassington; N V Marsh
Journal:  Neuropsychol Rev       Date:  1998-06       Impact factor: 7.444

8.  MRI lesion volume heterogeneity in primary progressive MS in relation with axonal damage and brain atrophy.

Authors:  D Pelletier; S J Nelson; J Oh; J P Antel; M Kita; S S Zamvil; D E Goodkin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-07       Impact factor: 10.154

9.  Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden.

Authors:  Ralph H B Benedict; Bianca Weinstock-Guttman; Inna Fishman; Jitendra Sharma; Christopher W Tjoa; Rohit Bakshi
Journal:  Arch Neurol       Date:  2004-02

10.  Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients.

Authors:  C Christodoulou; L B Krupp; Z Liang; W Huang; P Melville; C Roque; W F Scherl; T Morgan; W S MacAllister; L Li; L A Tudorica; X Li; P Roche; R Peyster
Journal:  Neurology       Date:  2003-06-10       Impact factor: 9.910

View more
  10 in total

1.  Normal-appearing white matter permeability distinguishes poor cognitive performance in processing speed and working memory.

Authors:  A Eilaghi; A Kassner; I Sitartchouk; P L Francis; R Jakubovic; A Feinstein; R I Aviv
Journal:  AJNR Am J Neuroradiol       Date:  2013-05-30       Impact factor: 3.825

Review 2.  Future Brain and Spinal Cord Volumetric Imaging in the Clinic for Monitoring Treatment Response in MS.

Authors:  Tim Sinnecker; Cristina Granziera; Jens Wuerfel; Regina Schlaeger
Journal:  Curr Treat Options Neurol       Date:  2018-04-20       Impact factor: 3.598

3.  Presynaptic, release-regulating mGlu2 -preferring and mGlu3 -preferring autoreceptors in CNS: pharmacological profiles and functional roles in demyelinating disease.

Authors:  Silvia Di Prisco; Elisa Merega; Tommaso Bonfiglio; Guendalina Olivero; Chiara Cervetto; Massimo Grilli; Cesare Usai; Mario Marchi; Anna Pittaluga
Journal:  Br J Pharmacol       Date:  2016-03-03       Impact factor: 8.739

Review 4.  Sexual dysfunction in patients with multiple sclerosis: a multidisciplinary approach to evaluation and management.

Authors:  Sophie G Fletcher; Wanda Castro-Borrero; Gina Remington; Katherine Treadaway; Gary E Lemack; Elliot M Frohman
Journal:  Nat Clin Pract Urol       Date:  2009-02

5.  Association between a genetic variant of type-1 cannabinoid receptor and inflammatory neurodegeneration in multiple sclerosis.

Authors:  Silvia Rossi; Marco Bozzali; Monica Bari; Francesco Mori; Valeria Studer; Caterina Motta; Fabio Buttari; Mara Cercignani; Paolo Gravina; Nicolina Mastrangelo; Maura Castelli; Raffaele Mancino; Carlo Nucci; Fabrizio Sottile; Sergio Bernardini; Mauro Maccarrone; Diego Centonze
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

6.  Prophylactic versus Therapeutic Fingolimod: Restoration of Presynaptic Defects in Mice Suffering from Experimental Autoimmune Encephalomyelitis.

Authors:  Tommaso Bonfiglio; Guendalina Olivero; Elisa Merega; Silvia Di Prisco; Cristina Padolecchia; Massimo Grilli; Marco Milanese; Lorenzo Di Cesare Mannelli; Carla Ghelardini; Giambattista Bonanno; Mario Marchi; Anna Pittaluga
Journal:  PLoS One       Date:  2017-01-26       Impact factor: 3.240

Review 7.  CCL5-Glutamate Cross-Talk in Astrocyte-Neuron Communication in Multiple Sclerosis.

Authors:  Anna Pittaluga
Journal:  Front Immunol       Date:  2017-09-04       Impact factor: 7.561

8.  Correlation between white matter damage and gray matter lesions in multiple sclerosis patients.

Authors:  Xue-Mei Han; Hong-Ji Tian; Zheng Han; Ce Zhang; Ying Liu; Jie-Bing Gu; Rohit Bakshi; Xia Cao
Journal:  Neural Regen Res       Date:  2017-05       Impact factor: 5.135

9.  Effects of Dimethyl Fumarate on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: Pooled Analysis Phase 3 DEFINE and CONFIRM Studies.

Authors:  Kunio Nakamura; Oksana Mokliatchouk; Douglas L Arnold; Tarek A Yousry; Ludwig Kappos; Nancy Richert; Katherine Ayling-Rouse; Catherine Miller; Elizabeth Fisher
Journal:  Front Neurol       Date:  2022-03-18       Impact factor: 4.003

10.  Clinical significance of cortical lesions in patients with multiple sclerosis: A neuropsychological and neuroimaging study.

Authors:  Futoshi Matsushita; Hirotaka Kida; Ken-Ichi Tabei; Chizuru Nakano; Keita Matsuura; Yuichiro Ii; Ryogen Sasaki; Akira Taniguchi; Yugo Narita; Masayuki Maeda; Masayuki Satoh; Hidekazu Tomimoto
Journal:  Brain Behav       Date:  2018-02-14       Impact factor: 2.708

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.